Skip to main content
Erschienen in: Breast Cancer Research 1/2023

Open Access 01.12.2023 | Retraction Note

Retraction Note: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer

verfasst von: Rifat Jan, Min Huang, Joan Lewis-Wambi

Erschienen in: Breast Cancer Research | Ausgabe 1/2023

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​bcr3356.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Retraction Note to: Breast Cancer Research 2012, 14:R146 https://​doi.​org/​10.​1186/​bcr3356
The Editor-in-Chief has retracted this article at the Corresponding Author's request. After publication, concerns were raised regarding the western blot images presented in the figures. Specifically:
  • Figure 1a beta-actin bands appear highly similar to Fig. 5b in the corresponding author's earlier article [1].
    Figure 7d pSer167-ER-alpha blot appears highly similar to the MCF:2A BCL-2 blot in Fig. 4a in the authors' earlier article [2].
  • Figure 2b pER-Ser118 blot appears to contain an “invisible” band in lane 3.
  • Figure 3b PEDF blot appears to have a vertical straight line break in the backgrounds between lanes 2 and 3.
  • Figure 4a PEDF lanes 2 and 3 appear highly similar to p70S6K lanes 1 and 2, respectively.
  • Figure 7d pAKT blot appears highly similar to Fig. 4d mitochondria Cyt c in [2].
    Figure 6d PBS and rPEDF images appear highly similar to Fig. 6d BSO and E2, respectively, in [2].
The Corresponding Author has stated that some of the blots from their other projects were mistakenly used in this article. The Editor-in-Chief therefore no longer has confidence in the presented data.
The authors have been offered to submit a revised manuscript with the correct data for further peer review.
Min Huang and Joan Lewis-Wambi agree to this retraction. The publisher has not been able to obtain a current email address for Rifat Jan.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Retraction Note: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer
verfasst von
Rifat Jan
Min Huang
Joan Lewis-Wambi
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2023
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-023-01711-7

Weitere Artikel der Ausgabe 1/2023

Breast Cancer Research 1/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.